Arch Neurol. 2012;69(2):191-197. doi:10.1001/archneurol.2011.971
Objective To explore cell subsets and molecules that changed specifically in patients with multiple sclerosis (MS) who had an optimal response to natalizumab. Natalizumab is a monoclonal antibody that inhibits the migration of activated immune cells to the central nervous system. It shows high efficacy in modifying the natural history of MS and induces freedom of disease activity in about 40% of treated patients with MS.
Design Prospective study of intrathecal immunoglobulin synthesis and cerebrospinal fluid lymphocyte subsets in patients with MS before and 1 year after beginning treatment with natalizumab. We monitored clinical and magnetic resonance imaging activity during a median time of 2 years.
Setting Two tertiary hospitals from the Spanish National Health Service.
Patients A total of 23 patients with MS.
Main Outcome Measures The differences between patients free of disease activity and patients with active disease during treatment.
Results Of the 23 patients, 10 (43.5%) remained free of disease activity during follow-up. The remaining 13 patients (56.5%) had relapses or new lesions despite natalizumab therapy. We did not find differences in demographic variables or clinical data between both groups prior to natalizumab therapy. All patients showed a decrease in cerebrospinal fluid CD4+ cells regardless of their response to treatment. Conversely, only patients free of disease activity showed a decrease in local IgM and, to a lesser extent, in IgG synthesis. They also showed lower percentages of B cells, particularly of CD5+ and plasmablast subsets that virtually disappeared after treatment with natalizumab.
Conclusion These data indicate that inhibition of intrathecal antibody synthesis is associated with a complete therapeutic response to natalizumab in patients with aggressive MS.
Author Affiliations: Red Española de Esclerosis Múltiple (Drs Villar, García-Sánchez, Costa-Frossard, Espiño, Roldán, Páramo, Lucas, Izquierdo, and Álvarez-Cermeño), Departments of Immunology (Drs Villar, Espiño, and Roldán) and Neurology (Drs Costa-Frossard and Álvarez-Cermeño), Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (Drs Villar, Costa-Frossard, Espiño, Roldán, and Álvarez-Cermeño), and Department of Medicine, University of Alcalá, Alcalá de Henares (Dr Álvarez-Cermeño), Madrid, and Departments of Neurology (Drs García-Sánchez, Páramo, and Izquierdo) and Molecular Biology (Dr Lucas), Hospital Virgen Macarena, Sevilla, Spain.
Source : AAN
..Comments for each blog posting are always appreciated.
Please use the link found below, to leave comments.. .. All comments are moderated to reduce SPAM and bad language ..
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
– Click here to: REGISTER – For our MS weekly e-Newsletter
“Providing You with ‘MS Views and News’, IS What We Do”
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews